Amylyx Pharmaceuticals, Inc. (AMLX)

Over the past six months, Amylyx Pharmaceuticals' stock has experienced significant events, delivering 74% gains over the last three months and 167% returns year-over-year. Wall Street analysts generally maintain a "Moderate Buy" consensus with an average price target of $16.75. Amylyx has faced a securities fraud class action lawsuit alleging overstated commercial prospects for Relyvrio and a legal inquiry into potential breaches of fiduciary duty. Amylyx announced updates on ongoing clinical studies in October 2025, including a Phase 1 study for AMX0114 for ALS and a Phase 3 study for Avexitide in post-bariatric hypoglycemia.

There is no specific information available to indicate significant demand seasonality for Amylyx Pharmaceuticals, Inc.'s products or services. Demand for its products is typically driven by patient need and medical prescription rather than seasonal fluctuations.

Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on developing therapies for neurodegenerative diseases and endocrine disorders. The company's major product candidates include AMX0035 and Avexitide. AMX0035, known as Relyvrio for ALS treatment, was voluntarily withdrawn from the market in April 2024 due to unconvincing Phase 3 clinical trial results. The company is advancing Avexitide for post-bariatric hypoglycemia and congenital hyperinsulinism and is conducting a Phase 1 study for AMX0114 for ALS.

Amylyx Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, USA. While Relyvrio was previously marketed in the U.S. and Canada, its withdrawal indicates a primary operational focus from its U.S. base for ongoing clinical development programs.

Amylyx Pharmaceuticals' brand reputation has been significantly impacted by the voluntary withdrawal of Relyvrio in April 2024, following unconvincing Phase 3 clinical trial results, leading to legal challenges. Despite this setback, the company is recognized for its commitment to addressing unmet medical needs and its mission-driven leadership team, with ongoing clinical development programs contributing to its standing in the biotech industry.

Amylyx Pharmaceuticals, Inc. has a diverse ownership structure, with approximately 91.64% held by institutional shareholders and 61.95% by insiders. Major institutional owners include Adage Capital Partners Gp, L.L.C., Perceptive Advisors Llc, and TCG Crossover Management, LLC. Morningside Venture Investments Ltd is the largest individual shareholder, owning 26.09 million shares representing 29.27% of the company.